Australia · Delayed Price · Currency is AUD Avecho Biotechnology Earnings Call Transcripts
Fiscal Year 2026
-
A positive interim analysis in a large phase III trial for a proprietary CBD insomnia capsule showed efficacy and strong safety, with the trial continuing to full enrollment. The result de-risks the program, accelerates commercialization plans, and supports global licensing and regulatory strategies.
-
A pivotal phase III trial for a TPM-enhanced CBD insomnia treatment is nearing interim analysis, with strong safety data and robust design validated by regulators. Commercial and regulatory pathways are clear, with Sandoz as a partner and global expansion planned if results are positive.
-
A proprietary CBD capsule for insomnia, enhanced with TPM technology, is in a pivotal phase III trial with interim results due in June. A major licensing deal with Sandoz secures Australian rights, with significant revenue potential and global expansion opportunities.